A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
Part of paid clinical trials in Miami Lakes, Florida.
- Sponsor
- Merck Sharp & Dohme LLC
- Study ID
- NCT07348237
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Chronic Kidney Failure
- End-Stage Renal Disease
- Renal Impairment
Eligibility Criteria
- Sex
- ALL
- Age
- 24 Years - 85 Years
- Healthy Volunteers
- Accepted
Interventions
- MK-2828 — DRUGOral administration
Study Details
The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.
Key Dates
- Start date
- Mar 2, 2026
- Status verified
- May 2026
- Primary completion
- Jul 20, 2026
- Completion
- Jul 20, 2026
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Severe Renal ImpairmentParticipants with severe renal impairment will receive a single dose of MK-2828 on Day 1
- Experimental: End Stage Renal Disease (ESRD) on Hemodialysis (HD)Participants with ESRD will receive a single dose of MK-2828 on Day 1 in each of 2 periods, with a washout of at least 14 days between doses.
- Experimental: Healthy Mean Matched ControlParticipants with normal renal function will receive a single dose of MK-2828 on Day 1
Primary Outcome Measure
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of MK-2828 in Plasma [ Time Frame: Pre dose and at designated time points up to 192 hours post dose ]
Central Contacts
- Toll Free Number1-888-577-8839
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Floridian Clinical Research ( Site 0001) | Miami Lakes | Florida | 33016 | Study Coordinator 305-330-9977 |
| Panax Clinical Research ( Site 0003) | Miami Lakes | Florida | 33014 | Study Coordinator 305-698-4500 |
| Orlando Clinical Research Center ( Site 0002) | Orlando | Florida | 32809 | Study Coordinator 407-240-7878 |
Find similar trials in Miami Lakes, FL
Related Studies
- Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF SystemRecruiting · C. R. Bard · La Jolla, California
- CSP #2026 - Beta Blocker Dialyzability on Cardiovascular OutcomesPHASE3 · Recruiting · VA Office of Research and Development · Long Beach, California
- Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic FunctionPHASE1 · Recruiting · Atea Pharmaceuticals, Inc. · Orlando, Florida
- Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery OutcomesRecruiting · 3ive Labs · Weston, Florida